RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat myeloma: teclistamab trial in japan
Disease control CompletedThis study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental CAR-T therapy shows early promise in Tough-to-Treat myeloma
Disease control CompletedThis early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goal…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail shows promise for relapsed myeloma
Disease control CompletedThis phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and resu…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 13:41 UTC